Designing Disruptive Business Models For Unmet Medical Need
An Interview With In Vivo Rising Leader Michael Hufford
An undergraduate class in abnormal psychology and a lifelong interest in technology helped to set Michael Hufford on a career path that now includes the co-founding of five companies. As CEO of Harm Reduction Therapeutics, a nonprofit pharmaceutical company, Hufford hopes to make a cheap, OTC version of naloxone widely available to help prevent unnecessary deaths from opioid overdoses.
You may also be interested in...
Seeking to improve on cumbersome, unreliable paper diaries for capturing patient experience data in pharmaceutical clinical trials, Invivodata is integrating Palm computing with a scientific, subject-centered approach to data collection that relies on repeated samplings to focus on the patient's current, immediate state in his or her natural environment.
Fresenius Kabi’s decision to add radio frequency-identification (RFID) tags to 24 products used in hospital operating rooms will help the company’s hospital pharmacy customers reduce waste, increase efficiencies and facilitate tighter medication inventory control, executives claim. However, only 10% of US hospitals are currently equipped to scan and process RFID tags, despite larger adoption rates in other industry sectors. COVID-19-related revenue losses may push more hospitals to adopt automated RFID medication management systems to save time and reduce labor costs.
An early childhood fascination with the natural world led Cesar de la Fuente into the fields of microbiology and immunology. A PhD from the University of British Columbia – and postdoc work at Massachusetts Institute of Technology – helped him combine computer science principles with biological processes. As the leader of a machine biology group and lab at the University of Pennsylvania, de la Fuente is working to develop new antibiotics to treat deadly bacterial infections.